Similar responses were observed in a phase II study conducted by the Groupe Francophone de Myélodysplasies (GFM), where observed CR rates were 47% and 17% in patients with TP53-mutated MDS and AML, respectively [79]. This evidence concerns the gene TP53 and acute myeloid leukemia.